Abstract
Clinical trials of chimeric antigen receptor (CAR)-modified T cells have shown promise in hematologic malignancies. However, in solid tumors, the clinical responses have been less impressive. It is important to determine how to further improve the clinical effects of CAR-modified T cells. In this review, we focus on recent clinical trials and analyze the factors that determine clinical responses, including the following: 1) the composition of the CAR; 2) the preparation of CAR-modified T Cells; 3) the clinical treatment schedule; 4) the patient characteristics. We also propose future Strategies that must be investigated before the technology can be used in a wider range of clinical applications.
Keywords: Adoptive cell therapy, chimeric antigen receptor, T cell, cancer immunotherapy, cancer gene therapy, clinical trial, T cell receptor, single chain fragment variable
Current Gene Therapy
Title:Strategies to Improve the Clinical Performance of Chimeric Antigen Receptor-Modified T Cells for Cancer
Volume: 13 Issue: 1
Author(s): Qing Zhang, Huizhong Li, Jie Yang, Liantao Li, Baofu Zhang, Jia Li and Junnian Zheng
Affiliation:
Keywords: Adoptive cell therapy, chimeric antigen receptor, T cell, cancer immunotherapy, cancer gene therapy, clinical trial, T cell receptor, single chain fragment variable
Abstract: Clinical trials of chimeric antigen receptor (CAR)-modified T cells have shown promise in hematologic malignancies. However, in solid tumors, the clinical responses have been less impressive. It is important to determine how to further improve the clinical effects of CAR-modified T cells. In this review, we focus on recent clinical trials and analyze the factors that determine clinical responses, including the following: 1) the composition of the CAR; 2) the preparation of CAR-modified T Cells; 3) the clinical treatment schedule; 4) the patient characteristics. We also propose future Strategies that must be investigated before the technology can be used in a wider range of clinical applications.
Export Options
About this article
Cite this article as:
Zhang Qing, Li Huizhong, Yang Jie, Li Liantao, Zhang Baofu, Li Jia and Zheng Junnian, Strategies to Improve the Clinical Performance of Chimeric Antigen Receptor-Modified T Cells for Cancer, Current Gene Therapy 2013; 13 (1) . https://dx.doi.org/10.2174/1566523211313010007
DOI https://dx.doi.org/10.2174/1566523211313010007 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Molecular Machinery Regulating Apoptosis Signal Transduction and its Implication in Human Physiology and Pathophysiologies
Current Molecular Medicine Potential Health Benefits of Passion Fruit Peel Flour
The Natural Products Journal Synthesis and Anticancer Activity of Some 2-[3/4-(2-Substituted Phenyl-2- oxoethoxy)benzylidene]-6-substituted-2,3-dihydro-1H-inden-1-one Derivatives
Letters in Drug Design & Discovery Flavonoid Antioxidants
Current Medicinal Chemistry Nanostructured Polyaniline: Synthesis and Application for Photothermal Cancer Therapy
Current Applied Polymer Science Editorial: Prostate Cancer Immunotherapy
Current Cancer Therapy Reviews Nanosponge: A Novel Carrier for Drug Delivery
Drug Delivery Letters Graphical Abstracts
Letters in Drug Design & Discovery Drug Disposition in Pathophysiological Conditions
Current Drug Metabolism Genetic Vaccination for the Active Immunotherapy of Cancer
Current Gene Therapy Electroporation Advances in Large Animals
Current Gene Therapy New Target Antigens for Cancer Immunoprevention
Current Cancer Drug Targets Targeting CSC-Related miRNAs for Cancer Therapy by Natural Agents
Current Drug Targets Current and Future Prospective of a Versatile Moiety: Imidazole
Current Drug Targets Flavonoids as Anticancer Agents: Recent Progress and State of the Art?
Current Organic Chemistry Application of In Vivo Electroporation to Cancer Gene Therapy
Current Gene Therapy Progresses in TCM Metal-Based Antitumour Agents
Anti-Cancer Agents in Medicinal Chemistry Topical and Transdermal Delivery of Drug-Loaded Nano/ Microsystems with Application of Physical Enhancement Techniques
Current Drug Targets Anti-Tumor Mechanisms of Novel 3-(4-Substituted Benzyl)-5-Isopropil-5- Phenylhydantoin Derivatives in Human Colon Cancer Cell Line
Anti-Cancer Agents in Medicinal Chemistry Antibody Penetration Into Living Cells: Pathogenic, Preventive and Immuno-Therapeutic Implications
Current Pharmaceutical Design